Image not available

Gharaei B et al, 2013: Opioid-sparing effect of preemptive bolus low-dose ketamine for moderate sedation in opioid abusers undergoing extracorporeal shock wave lithotripsy: a randomized clinical trial

Gharaei B, Jafari A, Aghamohammadi H, Kamranmanesh M, Poorzamani M, Elyassi H, Rostamian B, Salimi A
Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Abstract

BACKGROUND: Ketamine has been used as part of a multimodal analgesia regime in opioid abusers undergoing general anesthesia. We studied the opioid-sparing effect of a very low-dose bolus of ketamine as part of moderate sedation for opioid abuse patients undergoing extracorporeal shock wave lithotripsy.

METHODS: In this randomized, placebo-controlled clinical trial, 190 opioid abusers were enrolled. They were stratified into 2 blocks based on their daily opioid consumption. Both blocks were then randomized to receive 0.1 mg/kg IV ketamine (group K) or placebo (group P). Lithotripsy was performed under moderate sedation with intermittent bolus doses of remifentanil (0.2 μg/kg) to alleviate pain. The total remifentanil dose (primary outcome) and respiratory adverse events (secondary outcome) were compared in the 2 groups.

RESULTS: Remifentanil administration in the group with low-opioid consumers was 1.6 ± 0.4 μg/kg (group P) compared with 1.0 ± 0.2 μg/kg in group K (confidence interval [CI]of difference 95%, 0.4–0.7; P < 0.001). Patients who had high-opioid consumption received 2.0 ± 0.5 μg/kg (group P) vs 1.5 ± 0.3 μg/kg (group K) remifentanil (CI of difference 95%, 0.40–0.75; P < 0.001). Ready to discharge time was statistically longer in high-consumption opioid abusers who received placebo compared with group K (55 ± 13 minutes vs. 44 ± 8 minutes, CI of difference 95%, 6–15; P < 0.001). The incidences of bradypnea, apnea, nausea, vomiting, and hemodynamic changes were not statistically different between the ketamine and placebo groups.

CONCLUSION: Preemptive low-dose ketamine (0.1 mg/kg) as a bolus has opioid-sparing effects in opioid abusers undergoing moderate sedation.

Anesth Analg. 2013 Jan;116(1):75-80. doi: 10.1213/ANE.0b013e31826f0622. Epub 2012 Dec 7
PMID:23223117 [PubMed - indexed for MEDLINE]

Rate this blog entry:
0
 

Comments 1

Peter Alken on Tuesday, 18 June 2013 09:03

There are no details related to the shock wave application as such in this anaesthesiological publication. As a clinician you should show this article to your anaesthetists.

Peter Alken

There are no details related to the shock wave application as such in this anaesthesiological publication. As a clinician you should show this article to your anaesthetists. Peter Alken
Guest
Monday, 21 August 2017
STORZ MEDICAL AG
Lohstampfestrasse 8
8274 Tägerwilen
Switzerland
Tel.: +41 (0)71 677 45 45
Fax: +41 (0)71 677 45 05

www.storzmedical.com
Personal data
Address
Contact data
Message